Akebia Therapeutics announces establishment of rare kidney disease pipeline

Akebia Therapeutics (AKBA) announced the establishment of its rare kidney disease pipeline. The pipeline is comprised of two core product candidates: ADX-097, a potential next generation complement inhibitor, now referred to as AKB-097, and praliciguat, a soluble guanylate cyclase stimulator. Akebia acquired all rights to AKB-097, a tissue-targeted C3d-Factor H fusion protein complement inhibitor, from Q32 Bio Inc. (QTTB) and believes AKB-097 has applicability across a wide range of complement-mediated rare kidney diseases. AKB-097 is targeted to the sites of complement activation in tissues and is not expected to result in systemic complement inhibition seen with other inhibitors. On November 28, 2025, Akebia and Q32 Bio signed an Asset Purchase Agreement under which Akebia acquired global rights to Q32 Bio’s ADX-097. In consideration, Akebia paid Q32 Bio an upfront payment of $7M. Akebia will also make a $3M payment upon the six-month anniversary of the closing, as well as additional development and regulatory milestones, commercial milestones and tiered royalties on annual net sales of AKB-097.